Study of Safety and Efficacy of an Oral Contraceptive
Launched by WARNER CHILCOTT · Jul 1, 2009
Trial Information
Current as of May 05, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy Women
- • Age 18-45
- • At risk for pregnancy
- • History of regular cycles
- Exclusion Criteria:
- • Contraindications for use of hormonal contraception
- • Conditions which affect the absorption or metabolism of steroid hormones
- • BMI \> 35
About Warner Chilcott
Warner Chilcott is a leading pharmaceutical company specializing in the development and commercialization of innovative prescription products in the fields of women's health, urology, and dermatology. With a commitment to enhancing patient outcomes, Warner Chilcott focuses on delivering high-quality medications that meet the evolving needs of healthcare providers and patients. The company is dedicated to rigorous clinical research and adherence to regulatory standards, ensuring the safety and efficacy of its therapies. Through strategic partnerships and a robust pipeline, Warner Chilcott continues to advance healthcare solutions that improve the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boynton Beach, Florida, United States
Miami, Florida, United States
Roswell, Georgia, United States
New Bern, North Carolina, United States
Winston Salem, North Carolina, United States
Philadelphia, Pennsylvania, United States
Sandy, Utah, United States
Virginia Beach, Virginia, United States
Seattle, Washington, United States
Phoenix, Arizona, United States
San Diego, California, United States
Jacksonville, Florida, United States
Louisville, Kentucky, United States
Pittsburgh, Pennsylvania, United States
Richmond, Virginia, United States
West Palm Beach, Florida, United States
Norfolk, Virginia, United States
Birmingham, Alabama, United States
Chico, California, United States
Los Angeles, California, United States
Denver, Colorado, United States
Palm Harbor, Florida, United States
Venice, Florida, United States
Decatur, Georgia, United States
Powder Springs, Georgia, United States
Savannah, Georgia, United States
Kansas City, Missouri, United States
St. Louis, Missouri, United States
Allentown, Pennsylvania, United States
Charleston, South Carolina, United States
Greenville, South Carolina, United States
Patients applied
Trial Officials
Herman Ellman, MD
Study Director
Sponsor GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials